---
audienceLevel: patient
cancerTypes:
- lung
- colorectal
- pancreatic
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Sotorasib - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/sotorasib
version: v1
---

# Sotorasib - NCI

# Sotorasib

Placeholder slot

(SOH-toh-RA-sib)

This page contains brief information about sotorasib
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Lumakras

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c80a362c-7ac3-4894-a076-0691e68ef8c1&audience=consumer)

## Use in Cancer

Sotorasib
is approved to treat adults whose cancer has an abnormal *[KRAS](/Common/PopUps/popDefinition.aspx?id=652256&version=Patient&language=English)* gene. It is used in:

- **[colorectal cancer](/Common/PopUps/popDefinition.aspx?id=444983&version=Patient&language=English)** that has spread to other parts of the body. It is used with [panitumumab](/Common/PopUps/popDefinition.aspx?id=397115&version=Patient&language=English) in patients who have received chemotherapy that included a [fluoropyrimidine](/Common/PopUps/popDefinition.aspx?id=386207&version=Patient&language=English), [oxaliplatin](/Common/PopUps/popDefinition.aspx?id=45465&version=Patient&language=English), and [irinotecan hydrochloride](/Common/PopUps/popDefinition.aspx?id=635811&version=Patient&language=English).
- **[non-small cell lung cancer](/Common/PopUps/popDefinition.aspx?id=45323&version=Patient&language=English)** (NSCLC). It is used in patients who have received at least one other [systemic therapy](/Common/PopUps/popDefinition.aspx?id=45922&version=Patient&language=English).¹

¹This use is approved under FDA’s [Accelerated Approval Program](https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm). As a condition of approval, [confirmatory trial(s)](/Common/PopUps/popDefinition.aspx?id=799146&version=Patient&language=English) must show that sotorasib provides a clinical benefit in these patients.

Sotorasib
is also being studied in the treatment of other types of
cancer.

## More About Sotorasib

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/794411) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Sotorasib](https://medlineplus.gov/druginfo/meds/a621036.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Can Chemo Help KRAS Inhibitors Work Better Against Pancreatic Cancer?](https://www.cancer.gov/news-events/cancer-currents-blog/2024/pancreatic-cancer-kras-inhibitors-chemotherapy)

[Can Targeted Therapy for KRAS Mutations Double as Part of Immunotherapy?](https://www.cancer.gov/news-events/cancer-currents-blog/2022/kras-targeted-drugs-as-immunotherapy)

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Sotorasib](https://www.cancer.gov/research/participate/clinical-trials/intervention/C154287) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
